Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy
Name
s41598-019-56943-5.pdf
Description
Published version
Size
2.54 MB
Format
Adobe PDF
Checksum (MD5)
7673481ac6524b7beedc4083522cfa0b
Author(s)
Truex, Nicholas
Holden, Rebecca Lynn
Wang, Bin-You
Chen, Pu-Guang
Hanna, Stephanie
Hu, Zhuting
Shetty, Keerthi
Olive, Oriol
Neuberg, Donna
Hacohen, Nir
Date Issued
January 2020
Journal
Scientific Reports
Publisher
Springer Science and Business Media LLC
Citation
Truex, Nicholas L. "Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy." Scientific Reports 10, 1 (Janauary 2020): 723 © 2020 The Author(s)
Version
Final published version
Abstract
High-throughput genome sequencing and computation have enabled rapid identification of targets for personalized medicine, including cancer vaccines. Synthetic peptides are an established mode of cancer vaccine delivery, but generating the peptides for each patient in a rapid and affordable fashion remains difficult. High-throughput peptide synthesis technology is therefore urgently needed for patient-specific cancer vaccines to succeed in the clinic. Previously, we developed automated flow peptide synthesis technology that greatly accelerates the production of synthetic peptides. Herein, we show that this technology permits the synthesis of high-quality peptides for personalized medicine. Automated flow synthesis produces 30-mer peptides in less than 35 minutes and 15- to 16-mer peptides in less than 20 minutes. The purity of these peptides is comparable with or higher than the purity of peptides produced by other methods. This work illustrates how automated flow synthesis technology can enable customized peptide therapies by accelerating synthesis and increasing purity. We envision that implementing this technology in clinical settings will greatly increase capacity to generate clinical-grade peptides on demand, which is a key step in reaching the full potential of personalized vaccines for the treatment of cancer and other diseases.
MIT Department
Massachusetts Institute of Technology. Department of Chemistry
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/s41598-019-56943-5
